Donald R. Chase, a director at Bluejay Diagnostics, Inc. (NASDAQ:BJDX), purchased 12,500 shares of common stock on March 14, 2026.
The transaction was part of a private placement, totaling $25,000 at $2.00 per share.
The stock trades near its 52-week low of $1.65, currently at $1.72—below Chase's purchase price.
After the acquisition, Chase directly holds 12,525 shares. The director's investment follows a 77% decline in the stock over the past year.
According to Bond.az analysis, the stock appears undervalued based on its Fair Value assessment.
In other news, Bluejay Diagnostics completed a private placement of 62,500 shares at $2.00 per share, raising $125,000. The buyers were five board members.
Bluejay also fully exercised all prefunded warrants from its October 2025 placement, leaving no outstanding prefunded warrants. Total common shares outstanding are approximately 972,000.
The company sent a response letter to NorthStrive Fund II LP, but the content was not disclosed.
